Pfizer Inc. Says Patient Died in Oral RA Drug Study

WSJ -- Pfizer said four patients enrolled in a trial studying its oral rheumatoid arthritis drug tofacitinib died during or after treatment, but that only one death has been linked to the drug, the WSJ reports. Full results of the study are due to be presented May 27 at a scientific meeting in London.

Brain-Injury Benefits: The chief of staff for Gabrielle Giffords, the congresswoman recovering from a January shooting, has urged HHS head Kathleen Sebelius to include high-quality brain-injury treatment and rehab in the list of essential benefits that must be provided by individual and small-business health-insurance policies, the Washington Post reports. Separately, staffers are urging the Defense Department to cover more comprehensive rehab for brain-injured servicemen and women through the military’s Tricare insurance program.